Overview

A Study of Pazopanib With CAPEOX in AGC Patients

Status:
Completed

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

In order to improve survival of metastatic gastric cancer patients, we plan to to conduct a phase II trial of CapeOx with 800 mg once-daily pazopanib as a first-line chemotherapy in metastatic gastric cancer patients.

Phase:

Phase 2

Details

Lead Sponsor:

Samsung Medical Center

Treatments:

Capecitabine
Oxaliplatin